Patient derived xenograft models
Research type
Research Study
Full title
Patient derived xenograft models to evaluate the pharmacokinetics and pharmacodynamics of cancer therapeutic agents
IRAS ID
251940
Contact name
Christopher Ireson
Contact email
Sponsor organisation
Pharmidex
Duration of Study in the UK
4 years, 11 months, 31 days
Research summary
Greater than 1 in 3 individuals develop cancer during their lifetime and the disease is one of the leading causes of death. In the last thirty years, there has been notable clinical success in the treatment of certain cancers, prominent amongst which are acute childhood leukaemia, testicular and breast cancer, whereas in other cancers, e.g. lung, the improvements in survival have been more modest. There is an urgent unmet clinical requirement for novel treatment strategies in order to increase the survival time and quality of life of the cancer patient. The aim of this project is to develop PDX models, to enable evaluation of novel cancer therapeutic agents. The project may also look for the identification and validation of novel biomarkers for other disorders including but not limited to respiratory and metabolic disorders and neurological disorders such as Alzheimer’s disease.\n\nWhilst there has been considerable progress in the development of pre-clinical models which recapitulate the clinical disease during the past three decades, the ability of these models to predict the clinical response to therapeutic agents is considered to be limited (Ireson et al., 2018, in press). Patient derived xenograft (PDX) models, in which tumours freshly resected from patients are implanted into mice, may have greater clinical relevance.
REC name
London - Camden & Kings Cross Research Ethics Committee
REC reference
18/LO/1888
Date of REC Opinion
26 Oct 2018
REC opinion
Favourable Opinion